Back to Results
First PageMeta Content
Laboratory techniques / Molecular biology / Polymerase chain reaction / Leukemia / Minimal residual disease / Acute leukemia / Acute lymphoblastic leukemia / Real-time polymerase chain reaction / Immunoglobulin heavy chain / Biology / Science / Chemistry


Minimal Residual Disease (MRD) as a Surrogate Endpoint in ALL FDA Workshop, 18 April 2012, Silver Spring, MD Minimal residual disease in acute lymphoblastic leukemia Technical, economical, and validation – QC
Add to Reading List

Open Document

File Size: 919,69 KB

Share Result on Facebook

City

Zurich / Berlin / Rome / Prague / Amsterdam / Frankfurt / Sheffield / Glasgow / Vienna / Lisbon / London / Lille / Hamburg / Bristol / Rotterdam / Paris / /

Continent

Europe / /

Currency

AED / /

IndustryTerm

treatment protocol / /

MedicalCondition

genes T-ALL / Leukemia / Minimal Residual Disease / residual disease / disease / Leukaemia / mutations T-ALL / T-ALL / /

MedicalTreatment

treatment protocol / /

Organization

FDA / /

Person

Silver Spring / Sydney Randwick / /

/

Position

Chairman / /

RadioStation

BFM / /

Region

Singapore Australia / /

Technology

treatment protocol / recombination / /

URL

www.EuroMRD.org / /

SocialTag